ArticleGenome medicine2026
From aging to Alzheimer's disease: concordant brain DNA methylation changes in late life.
Article in Genome medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epigenetics in Alzheimer's disease: from molecular mechanisms to emerging novel biomarkers.Frontiers in aging neuroscience · 2026Review
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
backgroundAging is the strongest risk factor for Alzheimer's disease (AD), but the molecular connections between aging and AD remain unclear. DNA methylation (DNAm) is implicated in both processes.
methodsWe conducted a meta-analysis of DNAm in prefrontal cortex from two independent postmortem cohorts: the Religious Orders Study and Memory and Aging Project (ROSMAP) and Brains for Dementia Research (BDR). Age-associated CpG sites were identified using cohort-specific linear models adjusted for neuronal proportion, sex, and batch, followed by meta-analysis. We computed epigenetic age acceleration in brain samples as delta-age (DNAmAge - chronological age), and compared clinically diagnosed AD with cognitively unimpaired participants. Functional analyses included genomic feature enrichment, pathway analysis, brain-blood DNAm correlation, and colocalization with genome-wide association study (GWAS) loci. Prognostic relevance of age-associated CpGs was tested in the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset using Cox proportional hazards models for disease progression.
resultsWe identified 3264 CpG sites associated with aging; most were hypermethylated and enriched in promoters and CpG islands, and involved genes related to immune regulation and metabolism. Comparison with AD neuropathology-associated methylation showed substantial overlap, with nearly all shared CpGs and regions showing concordant directional changes. Cortical epigenetic age acceleration was higher in ROSMAP participants with clinical AD than in cognitively unimpaired individuals after covariates adjustment, and this association persisted when the cortical clock was restricted to the aging-associated CpGs identified here, suggesting that acceleration in AD is attributable to age-related CpGs. Several CpGs showed significant brain-blood methylation correlations or were linked to AD GWAS risk loci through colocalization analyses. In ADNI, among 33 candidate CpGs selected for concordant aging- and AD-associated changes in cortex and significant brain-blood methylation correlations, baseline methylation at one CpG (cg10752406 in AZU1 promoter) was associated with progression at a 5% false discovery rate after covariate adjustment.
conclusionsAging-associated DNAm changes in prefrontal cortex overlap with AD neuropathology-related changes and are involved in accelerated epigenetic aging in clinical AD. Our study provides valuable insights into the epigenetic landscape of aging and its implications for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.